Alnylam Pharma (ALNY) Misses Q2 EPS by 42c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $293.17 -0.3%
EPS Growth %: +409.4%
Financial Fact:
Loss from operations: -92.45M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +409.4%
Financial Fact:
Loss from operations: -92.45M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($2.03), $0.42 worse than the analyst estimate of ($1.61). Revenue for the quarter came in at $224.82 million versus the consensus estimate of $255.87 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk stock target lifted by Citi on continued demand strength
- Komodo Health expands AI platform deal with Alnylam
- Stifel reports May 2026 client assets rose 16% year-over-year
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
